Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13983006 | 0.81 | ALDH1A1 (0.63) | ALDH1A1IGF1RNPSR1LMNAMAPK1 | |
| SCHEMBL3584691 | 0.79 | RAB9A (0.56) | ALDH1A1NPSR1MAPK1 | |
| SCHEMBL28146850 | 0.74 | NPSR1 (0.56) | ALDH1A1NPSR1LMNAMAPK1CYP1A2 | |
| SCHEMBL4552206 | 0.73 | GABRA1 (0.31) | — | |
| SCHEMBL1126580 | 0.73 | NPSR1 (0.51) | ALDH1A1NPSR1LMNAMAPK1L3MBTL1 | |
| SCHEMBL6325990 | 0.71 | CYP1A2 (0.67) | ALDH1A1NPSR1LMNAMAPK1CYP1A2 | |
| SCHEMBL14236103 | 0.70 | NPSR1 (0.70) | ALDH1A1NPSR1LMNAMAPK1CYP1A2 | |
| SCHEMBL6321766 | 0.70 | CYP1A2 (0.58) | ALDH1A1IGF1RNPSR1LMNAMAPK1 | |
| SCHEMBL1627629 | 0.68 | HPGD (0.76) | ALDH1A1IGF1RLMNAMAPK1CYP1A2 | |
| SCHEMBL13919303 | 0.67 | IGF1R (0.61) | ALDH1A1IGF1RNPSR1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| EP-2076492-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008054605-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | ALDH1A1 2016/4885IGF1R 3756/4885NPSR1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.